A recent study confirms that a single-lead artificial intelligence (AI)-enabled electrocardiogram (ECG) serves as a powerful ...
L1, EBV and mismatch repair deficiency suggests CLDN18.2 stratification must be integrated into multi-biomarker algorithms ...
As the global burden of obesity, type 2 diabetes, and metabolic syndrome continues to rise, fatty liver disease has become ...
As the global burden of obesity, type 2 diabetes, and metabolic syndrome continues to rise, fatty liver disease has become one of the most prevalent ...
Germany: Researchers have discovered in a new study that among patients with chronic subdural hematoma undergoing burr hole ...
A research team in Xinjiang Uygur Autonomous Region in northwest China has developed a novel diagnostic technique that ...
Morning Overview on MSN
Deep brain stimulation is being tested as an option for treatment-resistant depression
A multi-center clinical trial is now enrolling patients to test whether surgically implanted electrodes delivering continuous ...
Morning Overview on MSN
Study identifies biomarker that may aid Parkinson’s and Lewy body diagnosis
Researchers have developed an infrared-based sensor that detects misfolded alpha-synuclein protein in spinal fluid with ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark approval for its Elecsys® Apolipoprotein E4 ...
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results